IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Sequoia Financial Advisors LLC

Sequoia Financial Advisors LLC raised its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,685 shares of the company’s stock after purchasing an additional 98 shares during the quarter. Sequoia Financial Advisors LLC’s holdings in IDEXX Laboratories were worth $697,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Empowered Funds LLC raised its stake in shares of IDEXX Laboratories by 2.8% in the 3rd quarter. Empowered Funds LLC now owns 1,310 shares of the company’s stock valued at $662,000 after acquiring an additional 36 shares during the period. Natixis Advisors LLC raised its stake in shares of IDEXX Laboratories by 8.0% in the 3rd quarter. Natixis Advisors LLC now owns 43,174 shares of the company’s stock valued at $21,812,000 after acquiring an additional 3,206 shares during the period. Mutual of America Capital Management LLC raised its stake in shares of IDEXX Laboratories by 0.6% in the 3rd quarter. Mutual of America Capital Management LLC now owns 11,240 shares of the company’s stock valued at $5,679,000 after acquiring an additional 68 shares during the period. Thrivent Financial for Lutherans raised its stake in shares of IDEXX Laboratories by 150.6% in the 3rd quarter. Thrivent Financial for Lutherans now owns 108,258 shares of the company’s stock valued at $54,693,000 after acquiring an additional 65,050 shares during the period. Finally, Quest Partners LLC raised its stake in shares of IDEXX Laboratories by 4,059.4% in the 3rd quarter. Quest Partners LLC now owns 2,870 shares of the company’s stock valued at $1,450,000 after acquiring an additional 2,801 shares during the period. 87.84% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other IDEXX Laboratories news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the completion of the transaction, the executive vice president now owns 8,176 shares in the company, valued at $3,781,645.28. The trade was a 54.98 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director M Anne Szostak sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, February 7th. The stock was sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company’s stock, valued at $1,426,242.34. This trade represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Trading Up 1.7 %

NASDAQ IDXX opened at $422.36 on Tuesday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88. The stock has a market capitalization of $34.35 billion, a PE ratio of 39.58, a price-to-earnings-growth ratio of 3.41 and a beta of 1.39. The firm has a 50 day moving average of $437.89 and a two-hundred day moving average of $446.30.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on IDXX shares. Piper Sandler boosted their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Leerink Partners started coverage on shares of IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 target price on the stock. Bank of America upped their target price on shares of IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Barclays upped their target price on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a research note on Tuesday, February 4th. Finally, Leerink Partnrs raised shares of IDEXX Laboratories to a “strong-buy” rating in a research note on Monday, December 2nd. Four analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $533.75.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.